Loyda Ylisastigui

912 total citations
17 papers, 735 citations indexed

About

Loyda Ylisastigui is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, Loyda Ylisastigui has authored 17 papers receiving a total of 735 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Virology, 11 papers in Immunology and 10 papers in Infectious Diseases. Recurrent topics in Loyda Ylisastigui's work include HIV Research and Treatment (14 papers), Immune Cell Function and Interaction (9 papers) and HIV/AIDS drug development and treatment (8 papers). Loyda Ylisastigui is often cited by papers focused on HIV Research and Treatment (14 papers), Immune Cell Function and Interaction (9 papers) and HIV/AIDS drug development and treatment (8 papers). Loyda Ylisastigui collaborates with scholars based in France, United States and Belgium. Loyda Ylisastigui's co-authors include David M. Margolis, Ronald J. Bosch, Nancie M. Archin, Jean Claude Gluckman, Jean Vizzavona, Abdelaziz Benjouad, Guocheng He, Abdelaziz Benjouad, Marc Parmentier and Loı̈c Martin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Virology and The Journal of Infectious Diseases.

In The Last Decade

Loyda Ylisastigui

17 papers receiving 722 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Loyda Ylisastigui France 12 502 349 260 241 89 17 735
Anuska Llano Spain 19 561 1.1× 286 0.8× 424 1.6× 217 0.9× 118 1.3× 47 853
Lori A. Emert‐Sedlak United States 16 390 0.8× 272 0.8× 198 0.8× 297 1.2× 97 1.1× 23 808
Yon Hwangbo United States 11 495 1.0× 316 0.9× 279 1.1× 230 1.0× 96 1.1× 13 794
G Croteau Canada 9 478 1.0× 516 1.5× 264 1.0× 130 0.5× 59 0.7× 14 874
Praveen K. Amancha United States 11 292 0.6× 162 0.5× 305 1.2× 135 0.6× 117 1.3× 26 638
J. C. Gluckman France 10 469 0.9× 190 0.5× 321 1.2× 165 0.7× 153 1.7× 21 664
Gustav Gilljam Sweden 13 326 0.6× 296 0.8× 136 0.5× 129 0.5× 212 2.4× 21 592
Jennifer Jones United States 11 511 1.0× 231 0.7× 388 1.5× 196 0.8× 138 1.6× 16 837
LEOTA HALL United States 7 398 0.8× 229 0.7× 134 0.5× 139 0.6× 142 1.6× 8 596
Daniah A. D. Thompson United States 7 687 1.4× 357 1.0× 461 1.8× 299 1.2× 57 0.6× 8 920

Countries citing papers authored by Loyda Ylisastigui

Since Specialization
Citations

This map shows the geographic impact of Loyda Ylisastigui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loyda Ylisastigui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loyda Ylisastigui more than expected).

Fields of papers citing papers by Loyda Ylisastigui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loyda Ylisastigui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loyda Ylisastigui. The network helps show where Loyda Ylisastigui may publish in the future.

Co-authorship network of co-authors of Loyda Ylisastigui

This figure shows the co-authorship network connecting the top 25 collaborators of Loyda Ylisastigui. A scholar is included among the top collaborators of Loyda Ylisastigui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loyda Ylisastigui. Loyda Ylisastigui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Burga, Rachel A., et al.. (2016). Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. Cytotherapy. 18(11). 1410–1421. 25 indexed citations
2.
Lehmann, Michael H., Stefan Walter, Loyda Ylisastigui, et al.. (2006). Extracellular HIV-1 Nef increases migration of monocytes. Experimental Cell Research. 312(18). 3659–3668. 22 indexed citations
3.
Ylisastigui, Loyda, H.L. Johnson, J Völker, et al.. (2005). Mitogen-Activated Protein Kinases Regulate LSF Occupancy at the Human Immunodeficiency Virus Type 1 Promoter. Journal of Virology. 79(10). 5952–5962. 20 indexed citations
4.
Ylisastigui, Loyda, Jason J. Coull, Victor C. Rucker, et al.. (2004). Polyamides Reveal a Role for Repression in Latency within Resting T Cells of HIV‐Infected Donors. The Journal of Infectious Diseases. 190(8). 1429–1437. 48 indexed citations
5.
Ylisastigui, Loyda, et al.. (2004). Coaxing HIV-1 from resting CD4 T cells. AIDS. 18(8). 1101–1108. 213 indexed citations
6.
He, Guocheng, Loyda Ylisastigui, & David M. Margolis. (2002). The Regulation of HIV-1 Gene Expression: The Emerging Role of Chromatin. DNA and Cell Biology. 21(10). 697–705. 44 indexed citations
7.
Bakri, Youssef, Abdelkrim Mannioui, Loyda Ylisastigui, et al.. (2002). CD40-Activated Macrophages Become Highly Susceptible to X4 Strains of Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses. 18(2). 103–113. 13 indexed citations
8.
Margolis, David M., Stephen Kewn, Jason J. Coull, et al.. (2002). The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir Is Associated With Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(1). 45–49. 64 indexed citations
9.
Vita, Claudio, Loyda Ylisastigui, Youssef Bakri, et al.. (2002). Synthesis and characterization of biologically functional biotinylated RANTES. Journal of Immunological Methods. 266(1-2). 53–65. 10 indexed citations
10.
Ylisastigui, Loyda, Youssef Bakri, Saaïd Amzazi, Jean Claude Gluckman, & Abdelaziz Benjouad. (2000). Soluble Glycosaminoglycans Do Not Potentiate RANTES Antiviral Activity on the Infection of Primary Macrophages by Human Immunodeficiency Virus Type 1. Virology. 278(2). 412–422. 10 indexed citations
11.
Shinya, Eiji, Xavier Dervillez, Florence Edwards‐Lévy, et al.. (1999). In-vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads. Biomedicine & Pharmacotherapy. 53(10). 471–483. 22 indexed citations
12.
Vizzavona, Jean, Loı̈c Martin, Andre Ménèz, et al.. (1999). Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proceedings of the National Academy of Sciences. 96(23). 13091–13096. 120 indexed citations
13.
Amzazi, Saaïd, Loyda Ylisastigui, Youssef Bakri, et al.. (1998). The Inhibitory Effect of RANTES on the Infection of Primary Macrophages by R5 Human Immunodeficiency Virus Type-1 Depends on the Macrophage Activation State. Virology. 252(1). 96–105. 35 indexed citations
14.
Ylisastigui, Loyda, Saaïd Amzazi, Youssef Bakri, et al.. (1998). Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2. Biomedicine & Pharmacotherapy. 52(10). 447–453. 10 indexed citations
15.
Ylisastigui, Loyda, Jean Vizzavona, Pascale Paindavoine, et al.. (1998). Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. AIDS. 12(9). 977–984. 68 indexed citations
16.
Seddiki, Nabila, Elisabeth Mbemba, Didier Letourneur, et al.. (1997). Antiviral activity of derivatized dextrans on HIV-1 infection of primary macrophages and blood lymphocytes. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1362(1). 47–55. 4 indexed citations
17.
Benjouad, Abdelaziz, et al.. (1997). HIV Type 1 V3 Peptide Constructs Act Differently on HIV Type 1 Infection of Peripheral Blood Lymphocytes and Macrophages. AIDS Research and Human Retroviruses. 13(3). 219–226. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anuska Llano Breakdown of academic impact, for papers by Lori A. Emert‐Sedlak Breakdown of academic impact, for papers by Yon Hwangbo Breakdown of academic impact, for papers by G Croteau Breakdown of academic impact, for papers by Praveen K. Amancha Breakdown of academic impact, for papers by J. C. Gluckman Breakdown of academic impact, for papers by Gustav Gilljam Breakdown of academic impact, for papers by Jennifer Jones Breakdown of academic impact, for papers by LEOTA HALL Breakdown of academic impact, for papers by Daniah A. D. Thompson
Rankless by CCL
2026